Current Trials

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Target: n/a Total: 2374

SPECIMEN COLLECTION AUGUSTA UNIVERSITY
Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations

AUGUSTA UNIVERSITY
Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute

Solid tumors/lymphoma that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival.
Screening Target: 6452 Screening Total: 6507
Intervention Target: 1425 Intervention Total: 778

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Target: 317 Total: 221

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Alternate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Target: 1475 Total: 1113

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

ATHENS & DEKALB MEDICAL
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

ATHENS & DEKALB MEDICAL
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

ATHENS & DEKALB MEDICAL
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

ATHENS, DEKALB MEDICAL & PHOEBE CANCER CENTER
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.

AUGUSTA UNIVERSITY, ATHENS, DEKALB MEDICAL & PHOEBE CANCER CENTER
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
Target: 1000 Total: 171

AUGUSTA UNIVERSITY
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Target: 210 Total: 132

AUGUSTA UNIVERSITY
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary.
Target: 128 Total: 49

AUGUSTA UNIVERSITY
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva
Target: 52 Total: 36

AUGUSTA UNIVERSITY & DEKALB MEDICAL
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial.
Target: 285 Total: 171

AUGUSTA UNIVERSITY
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Target: 188 Total: 97

AUGUSTA UNIVERSITY
A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Target: 147 Total: 17

AUGUSTA UNIVERSITY & DEKALB MEDICAL
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
Target: 488 Total: 32

AUGUSTA UNIVERSITY
Perfusion CT to Predict Progression-Free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Target: 184 Total: 0

AUGUSTA UNIVERSITY, DEKALB MEDICAL & MOOREHOUSE
Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?”
Target: 1150 Total: 1129

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
(EROS) Engendering Reproductive Health within Oncologic Survivorship
Target: 612 Total: 179

ATHENS
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Target: 576 Total: 310

ATHENS
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases
Target: 130 Total: 14

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Temporarily Closed to Accrual
Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Target: 660 Total: 204

AUGUSTA UNIVERSITY
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Target: 200 Total: 25

Temporarily Closed to Accrual
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)

Cohort 1 Closed
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL

AUGUSTA UNIVERSITY
A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-Cell lymphoma of the activated B-Cell subtype
Target: 302 Total: 24

AUGUSTA UNIVERSITY
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Target: 689 Total: 17

AUGUSTA UNIVERSITY, ATHENS, DEKALB MEDICAL & PHOEBE CANCER CENTER
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Target: 10000 Total: 1592

AUGUSTA UNIVERSITY, ATHENS, DEKALB MEDICAL & PHOEBE CANCER CENTER

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Target: 8300 Total: 3046

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Target: 450 Total: 194

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Target: 378 Total: 61

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Target: 714 Total: 338

AUGUSTA UNIVERSITY & DEKALB MEDICAL
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC
Target: 169 Total: 0

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Target: 300 Total: 140

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Temporarily Closed
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Target: 400 Total: 250

ATHENS
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Target: 148 Total: 39

AUGUSTA UNIVERSITY
The Caucasian/other races cohort is closed to accrual
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Target: 1000 Total: 1006

AUGUSTA UNIVERSITY
Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
Target: 172 Total: 48

AUGUSTA UNIVERSITY
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TRACER)
Target: 3960 Total: 1632

Implementation of Smoking Cessation Services within NCI NCORP Community Sites with Organized Lung Cancer Screening Program

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Target: 17230 Total: 16078

Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Target: 5872 Total: 8906

Temporarily Closed
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Target: 5437 Total: 5031